GEHCGE HealthCare

$71.45-2.5% 1Y

Is the price fair?

Good

Undemanding: cheap against its own history and cheap vs its sector.

2 good, 1 without data
Vs its own P/E rangecheaper than 79% of its own historyderived

Cheap vs its own history: P/E 16.4 vs a 19.1 median over 14 quarters (−14% vs median).

Vs sector (EV/EBIT)14.7×derived · Jun 30, 2026

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What GEHC's price assumes

GE HealthCare trades at 16.4× earnings against 28.1× for the median Medical Devices name, cheaper than its own group.

16.4

Trailing P/E · Medical Devices median 28.1 · cheaper than the typical name in its group

Price / sales
1.52

Price / sales · today's price, trailing year to Jun 30, 2026

Price / book
2.94

Price / book · today's price, trailing year to Jun 30, 2026

EV / sales
1.89

EV / sales

Details›
Price / booktoday's price, trailing year to Jun 30, 2026
2.94
EV / EBITtoday's price, trailing year to Jun 30, 2026
14.7
EV / salestoday's price, trailing year to Jun 30, 2026
1.89
Healthcare median P/E503 names
27.9
Medical Devices median P/E64 names
28.1
Market capitalisation451.7 million shares, counted Jul 22, 2026
$32.3B
What the market has paid for these earnings: 14 quarters of its own multiple × $4.36 of trailing earnings per share
MethodPer share
Its own P/E history, lower quartile$73.99
Its own P/E history, median$83.19
Its own P/E history, upper quartile$98.22
52-week range$59.49 – $88.08
Today$71.45

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Against its own past

Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.